Search
for
Sort by
Research 181–210 of 1000+
- Comorbidity in patients with alopecia areata
- Frontal fibrosing alopecia and ulerythema ophryogenes as two entites that can transist one into another
- Motivations and stake management in producing YouTube
- Highlights
- The eyelash comes to the fore
- Peer Review #3 of "Computational drug repositioning based on side-effects mined from social media (v0.3)"
- Peer Review #2 of "Computational drug repositioning based on side-effects mined from social media (v0.1)"
- Peer Review #1 of "Computational drug repositioning based on side-effects mined from social media (v0.1)"
- Commentary on: An Assessment of Gender Differences in Plastic Surgery Marketing in the United States: Are We Neglecting Our Male Patients?
- Global Council of Hair Restoration Surgery Societies Meets
- Ethics Consultation: from Theory to Practice
- Forensic Medicine: Clinical and Pathological Aspects
- Reply from the Authors
- The Acute Toxicity of 2,3,4,7,8-Pentachlorodibenzofuran (4PeCDF) in the Male Fischer Rat
- Industry news
- Metoprolol
- تقييم العوامل المؤثرة على الحالة الغذائية لمرض السمنة المصريين والعمانيين
- Studio prospettico a sei mesi sugli effetti di un prodotto topico in lozione e shampoo a base di timo-peptidi di sintesi a basso peso molecolare nel telogen effluvium cronico e nell'AGA iniziale della donna
- Assessment of Quality of Life and Treatment Outcomes of Patients With Persistent Postchemotherapy Alopecia
- Androgens in women
- Risks of minoxidil toxicity for household pets
- Hormonal Therapy for Acne
- Endocrine Therapy–Induced Alopecia in Patients With Breast Cancer
- Rethinking biotin therapy for hair, nail, and skin disorders
- Androgens in women
- Hair disorders in patients with cancer
- Nail changes in alopecia areata: an update and review
- Pharmacologic Modulation of Sebaceous Gland Activity: Mechanisms and Clinical Applications
- Case of de novo nail psoriasis triggered by the second dose of Pfizer-BioNTech BNT162b2 COVID-19 messenger RNA vaccine
- Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies